Compare EQT & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQT | WAT |
|---|---|---|
| Founded | 1925 | 1958 |
| Country | United States | United States |
| Employees | 1873 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 33.6B |
| IPO Year | 1994 | 1996 |
| Metric | EQT | WAT |
|---|---|---|
| Price | $56.21 | $345.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 17 |
| Target Price | $69.15 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 6.6M | 935.8K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 635.56 | 0.47 |
| EPS | 2.36 | ★ 10.76 |
| Revenue | ★ $8,644,211,000.00 | $3,165,286,000.00 |
| Revenue This Year | $20.28 | $104.66 |
| Revenue Next Year | N/A | $10.40 |
| P/E Ratio | ★ $24.47 | $32.49 |
| Revenue Growth | ★ 63.92 | 6.99 |
| 52 Week Low | $48.47 | $275.05 |
| 52 Week High | $68.24 | $414.15 |
| Indicator | EQT | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 62.02 |
| Support Level | $55.13 | $340.09 |
| Resistance Level | $57.62 | $397.85 |
| Average True Range (ATR) | 1.56 | 12.02 |
| MACD | -0.06 | 3.47 |
| Stochastic Oscillator | 15.77 | 82.98 |
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.